Latest amphotericin B Stories
VANCOUVER, Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced next steps for its Oral Amphotericin B program.
Scientists have solved a decades-old medical mystery – and in the process have found a potentially less toxic way to fight invasive fungal infections, which kill about 1.5 million people a year.
Company launches anti-fungal AmBisome® as one of the segment's first product offerings MUMBAI, India and PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc.
Scientists at the University of Massachusetts Medical School (UMMS) and the Wellcome Trust Sanger Institute have discovered evidence that a widely used anti-fungal medicine increases susceptibility to flu infection in mice and cell cultures.
Mice given a drug commonly used in patients to fight systemic fungal infections more often succumb to what would otherwise be a mild case of the flu.
The Amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease which in the Western world mainly affects dogs, but in developing countries affects over 12 million people, with more than 70,000 deaths per year.
The vision for a new branch of medicine, inspired by the ancient field that began with peg legs and hand hooks, commanded the spotlight in a major address by its pioneer here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
Neutron scattering experiments have provided new insights into the origin of the side effects of an antifungal drug prescribed all over the world.